Reality Check on IBS-C
Market access for irritable bowel syndrome with constipation (IBS-C) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, more than 42% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In September 2019, the FDA approved Ardelyx, Inc.'s Ibsrela (tenapanor) for the treatment of IBS-C in adults
- Key Findings: Contracting for preferred formulary status is expected to become more important in this indication as new agents are approved
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.